Traders should prepare for the earnings call on March 17 for potential updates on ZEVASKYN commercial performance, manufacturing capacity, and financial runway. Absence of data suggests this release is logistical, not substantive.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $4.94entry
- T+1 · 9mo ago +0.61%α −0.15% · $4.97
- T+5 · 8mo ago +4.05%α +4.53% · $5.14
- T+20 · 8mo ago −9.31%α −4.91% · $4.48
- T+60 · 6mo ago +15.18%α +4.87% · $5.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics announced it will discuss its fourth quarter and full year 2025 financial results on March 17, 2026, but did not release any actual financial data in this press release. The company highlighted its commercial-stage status with ZEVASKYN® and upcoming participation in the Leerink Global Healthcare Conference.
Key Facts
- Abeona Therapeutics will host an earnings call on March 17, 2026, to discuss Q4 and full year 2025 financial results.
- No financial results were disclosed in this press release.
- The company is commercializing ZEVASKYN®, an autologous cell-based gene therapy for RDEB.
- Management will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026.
- Forward-looking statements emphasize risks related to commercialization, manufacturing, regulatory approvals, and patient enrollment.
Financial Impact
No financial data released, impact cannot be quantified at this time
Risk Factors
- Risk that ZEVASKYN fails to gain market traction or that manufacturing cannot scale to meet demand.
- Regulatory risk related to FDA inspections of the cGMP manufacturing facility.
- Clinical trial enrollment challenges could delay development programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248223 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers